Could Denali Therapeutics Inc. (DNLI) Change Direction After Today’s Huge Increase?

April 17, 2018 - By Henry Gaston

The stock of Denali Therapeutics Inc. (NASDAQ:DNLI) is a huge mover today! The stock increased 5.42% or $1.01 during the last trading session, reaching $19.63. About 126,147 shares traded. Denali Therapeutics Inc. (NASDAQ:DNLI) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.
The move comes after 7 months positive chart setup for the $1.85B company. It was reported on Apr, 17 by Barchart.com. We have $20.81 PT which if reached, will make NASDAQ:DNLI worth $111.24 million more.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company has market cap of $1.85 billion. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It currently has negative earnings. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients.

Denali Therapeutics Inc. (NASDAQ:DNLI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.